Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Sterility & contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections.

6,317 FDA drug recalls with this cause, newest first.

This is the single biggest cause in the register by a wide margin. It covers products that had to be sterile - injectables, eye drops, certain ointments - but could not be verified sterile, or were found contaminated during testing. Most of these recalls come from compounding pharmacies and outsourcing facilities after an FDA inspection finds gaps in how sterile products were made. Sterility failures are treated seriously because the products involved have the least room for error, going straight into the bloodstream or the eye.

Class II · Moderate risk

norepinephrine Bitartrate

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Ongoing Sterility / contamination Fagron Compounding Services NDC 71266-5026-02 D-0438-2026
Class II · Moderate risk

Octreotide Acetate for Injectable Suspension

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Ongoing Sterility / contamination Teva Pharmaceuticals USA, Inc NDC 0480-9262-08 D-0406-2026
Class II · Moderate risk

Octreotide Acetate for Injectable Suspension

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Ongoing Sterility / contamination Teva Pharmaceuticals USA, Inc NDC 0480-9259-08 D-0405-2026
Class II · Moderate risk

Octreotide Acetate for Injectable Suspension

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Ongoing Sterility / contamination Teva Pharmaceuticals USA, Inc NDC 0480-9257-08 D-0404-2026
Class II · Moderate risk

Lanreotide Injection

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Ongoing Sterility / contamination Cipla USA, Inc. NDC 69097-906-67 D-0423-2026
Class II · Moderate risk

Lanreotide Injection

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Ongoing Sterility / contamination Cipla USA, Inc. D-0422-2026